Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy
10:41 EDT 3 Aug 2012 | Elsevier Business Intelligence
Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.
Original Article: Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy
More From BioPortfolio on "Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
